What Is the Difference Between Non-Classic CAH and PCOS?
At a Glance
Non-classic CAH and PCOS can both cause excess hair growth, irregular periods, acne, and multiple ovarian follicles, so symptoms alone cannot distinguish them. Morning 17-OHP testing, ACTH stimulation, and sometimes CYP21A2 testing help identify the cause.
If you were initially diagnosed with Polycystic Ovary Syndrome (PCOS) and your doctor is now evaluating you for Non-Classic Congenital Adrenal Hyperplasia (NC-CAH), it is completely normal to feel confused. These two conditions mimic each other very closely because both involve elevated levels of androgens (hormones like testosterone that are naturally present in all sexes) [1][2].
However, they have fundamentally different origins. NC-CAH is a genetic disorder affecting how the adrenal glands produce hormones, whereas PCOS is a complex reproductive and metabolic syndrome [3][4]. Because their symptoms look almost identical, a PCOS diagnosis officially requires doctors to rule out other conditions that mimic it, including NC-CAH [5][6]. Note that it is also possible for the two conditions to coexist in the same person.
The Difference in Origin
Non-Classic CAH is caused by inherited genetic variations, most commonly in the CYP21A2 gene [3][7]. This causes a partial deficiency in an enzyme called 21-hydroxylase. Without enough of this enzyme, the adrenal glands (small hormone-producing glands sitting above your kidneys) struggle to make certain hormones efficiently. This leads to a buildup of precursor hormones that the body converts into excess androgens [3]. It is an autosomal recessive condition, meaning a person typically must inherit an affected gene from both parents to develop it [7].
PCOS is a complex syndrome that does not have a single genetic cause [1]. It involves a combination of ovarian and sometimes adrenal factors, and is often tied to systemic issues like insulin resistance (when the body needs more insulin to control blood sugar) [6][8].
Why Symptoms Are Not Enough to Tell Them Apart
You cannot tell the difference between NC-CAH and PCOS based on physical symptoms or routine ultrasounds alone. Both conditions frequently cause:
- Hirsutism: Excess, dark hair growth on the face, chest, or back [1].
- Menstrual dysfunction: Irregular, infrequent, or absent menstrual periods [2].
- Multiple ovarian follicles: Often confusingly called “cysts,” having multiple small, undeveloped follicles on the ovaries can occur in both conditions due to prolonged androgen exposure [9][1]. An ultrasound showing a “string of pearls” appearance is not enough on its own to diagnose PCOS.
Note on Red Flags: If you experience a very rapid onset of severe symptoms—such as a suddenly deepening voice, clitoral enlargement, or rapidly progressing hair growth—this requires prompt medical evaluation. These rapid changes are not typical of PCOS or NC-CAH and may suggest another cause, such as an androgen-secreting tumor or a different endocrine disorder [5].
How Doctors Test for the Difference
Because clinical signs overlap so heavily, doctors rely on specific blood tests—and sometimes genetic tests—to identify the true source of the hormone imbalance.
- Basal 17-OHP Blood Test: The first step is usually a morning blood test to measure 17-hydroxyprogesterone (17-OHP), the precursor hormone that builds up when the 21-hydroxylase enzyme is partially deficient [10][11]. Ideally, this is drawn in the early morning during the first few days of your menstrual cycle, though this timing can be difficult to achieve if your periods are highly irregular. Cutoffs for what is considered “high” depend strongly on the specific laboratory and the type of assay (testing method) they use [12][13].
- ACTH Stimulation Test: If your baseline 17-OHP is elevated but borderline, your doctor may order an ACTH stimulation test. You will receive an injection of synthetic ACTH (a hormone that signals the adrenal glands to work), and your 17-OHP and cortisol levels are measured over 60 minutes [4]. If your 17-OHP rises past a specific, assay-validated threshold, it supports a diagnosis of NC-CAH [12]. This test also helps check your adrenal reserve (your adrenal gland’s ability to produce enough cortisol during stress) [14].
- Genetic Testing: Testing the CYP21A2 gene can serve as an adjunct to help confirm a diagnosis when blood tests are unclear [10]. It is technically complex, and a negative or uncertain result does not always override a clear biochemical diagnosis [15]. Genetic testing is especially important for reproductive counseling to understand the risks of passing a classic (more severe) form of CAH to your children [10].
Differences in Treatment
Treating non-fertility symptoms like acne, hair growth, and irregular periods often involves similar medications for both conditions. Doctors frequently prescribe oral contraceptives or anti-androgen medications (like spironolactone) [11][16]. Safety warning: Anti-androgens require highly reliable birth control and must be stopped if you are trying to conceive, as they can harm a developing fetus.
However, treating the underlying condition differs significantly:
- Glucocorticoid Therapy (Unique to NC-CAH): Because NC-CAH originates in the adrenal glands, specialists sometimes prescribe low-dose glucocorticoids (steroid medications such as hydrocortisone) to suppress the excess adrenal androgens. This can help restore ovulation and support fertility for those trying to conceive [11][17]. Importantly, most people with NC-CAH produce enough of their own baseline cortisol and do not routinely need chronic steroid replacement [3][18]. Glucocorticoids carry long-term risks like weight gain, high blood pressure, bone loss, and adrenal suppression, so they are only used when carefully selected by an endocrinologist [19][18]. If you do take them, medication choices must be adjusted during pregnancy (for example, dexamethasone crosses the placenta and is handled differently) and should never be altered without medical supervision [20].
- Metabolic and Ovarian Focus (PCOS): PCOS treatment often focuses on improving metabolic health and insulin resistance (using lifestyle modifications and medications like metformin) and inducing ovulation for fertility with medications like letrozole [6]. Routine glucocorticoids are not used for PCOS.
Common questions in this guide
Can symptoms alone tell me whether I have NC-CAH or PCOS?
What is the 17-OHP test used for when evaluating NC-CAH?
What happens if my 17-OHP result is borderline?
Can a person have both non-classic CAH and PCOS?
How do treatment approaches differ for NC-CAH and PCOS?
Should genetic testing or partner testing be considered with NC-CAH?
Which androgen-related changes need prompt medical evaluation?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Blood testing
Would a morning blood test for 17-hydroxyprogesterone help my doctor tell PCOS and NC-CAH apart?
Genetic testing
Could a genetic test of CYP21A2 help confirm my diagnosis if my blood tests are unclear?
Treatment options
Would oral contraceptives or spironolactone be considered for symptoms I am having, like acne or irregular periods?
Related questions
Show more
Get notified when new evidence is published on Congenital adrenal hyperplasia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (20)
- 1
Polycystic Ovary Syndrome and NC-CAH: Distinct Characteristics and Common Findings. A Systematic Review.
Papadakis G, Kandaraki EA, Tseniklidi E, et al.
Frontiers in endocrinology 2019; (10()):388 doi:10.3389/fendo.2019.00388.
PMID: 31275245 - 2
Clinical, Metabolic and Hormonal Overlap Between Nonclassic Congenital Adrenal Hyperplasia and Polycystic Ovary Syndrome: An Exploratory Study.
Yavuz A, Coskun A, Uzman DT, Hatipoglu E
Journal of clinical medicine 2026; (15(17)) doi:10.3390/jcm15176522.
PMID: 42739527 - 3
Nonclassic Congenital Adrenal Hyperplasia: What Do Endocrinologists Need to Know?
Jha S, Turcu AF
Endocrinology and metabolism clinics of North America 2021; (50(1)):151-165 doi:10.1016/j.ecl.2020.10.008.
PMID: 33518183 - 4
Differentiating Polycystic Ovary Syndrome from Adrenal Disorders.
Yesiladali M, Yazici MGK, Attar E, Kelestimur F
Diagnostics (Basel, Switzerland) 2022; (12(9)) doi:10.3390/diagnostics12092045.
PMID: 36140452 - 5
Congenital Adrenal Hyperplasia.
Török D
Experientia supplementum (2012) 2019; (111()):245-260 doi:10.1007/978-3-030-25905-1_12.
PMID: 31588535 - 6
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Wilkinson LD, Brady PH, Gin GT, Rosenblum E
FP essentials 2022; (515()):26-31.
PMID: 35420404 - 7
Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia.
Parsa AA, New MI
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):2-11 doi:10.1016/j.jsbmb.2016.06.015.
PMID: 27380651 - 8
Hyperinsulinemic-Euglycemic Clamp Strengthens the Insulin Resistance in Nonclassical Congenital Adrenal Hyperplasia.
Delai A, Gomes PM, Foss-Freitas MC, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(3)):e1106-e1116 doi:10.1210/clinem/dgab767.
PMID: 34693966 - 9
New characteristics of polycystic ovary syndrome phenotypes according to gas chromatography-mass spectrometry-based study of urinary steroid metabolome.
Yarmolinskaya MI, Glavnova OB, Vorokhobina NV, et al.
Minerva obstetrics and gynecology 2025; (77(2)):93-102 doi:10.23736/S2724-606X.24.05461-7.
PMID: 39016550 - 10
Clinical, Biochemical and Molecular Characteristics of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency
Odabaşı Güneş S, Peltek Kendirci HN, Ünal E, et al.
Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):3-11 doi:10.4274/jcrpe.galenos.2024.2024-6-6-S.
PMID: 39713855 - 11
Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.
Carmina E, Dewailly D, Escobar-Morreale HF, et al.
Human reproduction update 2017; (23(5)):580-599 doi:10.1093/humupd/dmx014.
PMID: 28582566 - 12
Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays.
Nakhleh A, Saiegh L, Shehadeh N, et al.
Frontiers in endocrinology 2022; (13()):1048663 doi:10.3389/fendo.2022.1048663.
PMID: 36704043 - 13
Serum 21-Deoxycortisol for Diagnosis of Nonclassic Congenital Adrenal Hyperplasia in Women With Androgen Excess.
Ng JL, Lim EM, Zhang R, et al.
The Journal of clinical endocrinology and metabolism 2023; (108(12)):e1560-e1570 doi:10.1210/clinem/dgad377.
PMID: 37358001 - 14
MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency.
Nordenström A, Falhammar H
European journal of endocrinology 2019; (180(3)):R127-R145.
PMID: 30566904 - 15
Molecular Diagnosis of Steroid 21-Hydroxylase Deficiency: A Practical Approach.
Arriba M, Ezquieta B
Frontiers in endocrinology 2022; (13()):834549 doi:10.3389/fendo.2022.834549.
PMID: 35422767 - 16
Non-classical congenital adrenal hyperplasia: current insights into clinical implications, diagnosis and treatment.
Loli P, Menotti S, di Filippo L, Giustina A
Endocrine 2025; (90(1)):1-16 doi:10.1007/s12020-025-04341-5.
PMID: 40699527 - 17
Reproduction and fertility issues in women with congenital adrenal hyperplasia: pathophysiology, management, and recent clinical advances.
Anaforoğlu İ, Ertörer ME
Hormones (Athens, Greece) 2026; doi:10.1007/s42000-026-00808-w.
PMID: 42443698 - 18
Case Report: Anastrozole as a monotherapy for pre-pubertal children with non-classic congenital adrenal hyperplasia.
Liu SC, Suresh M, Jaber M, et al.
Frontiers in endocrinology 2023; (14()):1101843 doi:10.3389/fendo.2023.1101843.
PMID: 36936152 - 19
Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.
Falhammar H, Nordenström A
Endocrine 2015; (50(1)):32-50 doi:10.1007/s12020-015-0656-0.
PMID: 26082286 - 20
Treatment and Follow-up of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Childhood and Adolescence
Peltek Kendirci HN, Ünal E, Dündar İ, et al.
Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):12-22 doi:10.4274/jcrpe.galenos.2024.2024-6-26-S.
PMID: 39713876
This comparison is for informational purposes only and does not constitute medical advice. An endocrinologist or other qualified clinician should interpret your 17-OHP results and guide decisions about NC-CAH, PCOS, treatment, and pregnancy planning.